The QXDx BCR-ABL %IS Kit
The QXDx BCR-ABL %IS Kit
Bio-Rad

Monitoring CML therapy

Bio-Rad releases first CE-IVD digital PCR test

Bio-Rad Laboratories announces the launch of the QXDx BCR-ABL %IS Kit, the first CE-IVD digital PCR test that can monitor the molecular response of patients with chronic myeloid leukemia (CML) to therapy. Chronic myeloid leukemia, or CML, is characterized by the "Philadelphia chromosome," a translocation of chromosomes 9 and 22 that results in BCR-ABL gene fusion. Tyrosine kinase inhibitors can target BCR-ABL kinase activity and can transform CML into a manageable chronic disease for many patients.

The global standard of care for managing CML, measuring BCR-ABL mRNA, however, falls short of clinicians' needs. There remains significant variation between laboratories as well as within laboratories that are using existing reverse transcription quantitative PCR (RT-qPCR) methods, which are not sensitive enough to determine whether a patient can discontinue therapy without risking disease recurrence.

The QXDx BCR-ABL %IS Kit provides an absolute measure of BCR-ABL transcripts with high reproducibility, precision, and sensitivity because it uses Bio-Rad's Droplet Digital PCR (ddPCR) technology. The kit is able to detect deep molecular response values of MR 4.7 or 5.0 in 2- or 4-well formats, which exceeds typical limitations of RT-qPCR-based tests that are reliable only down to MR 4.5. Its high sensitivity permits disease remission to be assessed more confidently, so can better aid clinicians in disease management decisions. It can be used with Bio-Rad's QX200 AutoDG ddPCR Dx System or with the QX200 ddPCR Dx System. The QXDx BCR-ABL %IS Kit uses QuantaSoft Software v1.7 for data acquisition and output. 


Source: Bio-Rad

06.12.2017

Related articles

The ‘sepsis team’

‘We are all aware of the importance of early diagnosis and rapid appropriate treatment of patients with severe sepsis. Yet, many patients still do not receive satisfactory early management and the…

Web advisories aid physicians

Monitoring and rapidly introducing new developments into everyday practice is an increasingly difficult task for many doctors. Additionally, patients are more informed due to media medical reports,…

Point-of-care testing

Moving towards deeper diagnostics with POCT

Just two decades ago, even though promising, point-of-care testing (POCT) was only used in hospitals and surgeries by a small number of specialists. Today POCT is in use throughout healthcare.

Related products

Lis, Middleware, POCT

i-SOLUTIONS Health - LabCentre

i-SOLUTIONS Health GmbH

Lis, Middleware, POCT

Medat - Laboratory Information Systems

Medat Computer-Systeme GmbH